A novel way of therapeutic angiogenesis using an adeno-associated virus-mediated angiogenin gene transfer.
- Author:
Young Hwa CHO
1
;
Hyun PARK
;
Eui Sic CHO
;
Wun Jae KIM
;
Bong Su KANG
;
Byung Yong PARK
;
Yeun Ju KIM
;
Young Ill LEE
;
Soo Ik CHANG
;
Keerang PARK
Author Information
1. Department of Biotechnology, Juseong College, Chungbuk 363-794, Korea. krpark@jsc.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
dependovirus;
angiogenesis;
angiogenin;
cardiovascular disease;
gene therapy
- MeSH:
Animals;
Cell Movement;
Cells, Cultured;
Dependovirus/*genetics;
Endothelial Cells/metabolism/*physiology;
*Gene Transfer Techniques;
Genetic Vectors;
Humans;
Male;
Mice;
Mice, Inbred C57BL;
*Neovascularization, Physiologic;
Ribonuclease, Pancreatic/biosynthesis/*genetics;
Umbilical Veins/cytology;
Vascular Endothelial Growth Factor A/biosynthesis
- From:Experimental & Molecular Medicine
2007;39(3):412-418
- CountryRepublic of Korea
- Language:English
-
Abstract:
To develop a novel therapeutic angiogenesis for the treatment of cardiovascular diseases, angiogenin (ANG1) was examined as a potential therapeutic gene. An adeno-associated virus (AAV)-mediated gene delivery system was used to measure the therapeutic efficacy of ANG1. Using a triple co-transfection technique, rAAV-ANG1-GFP, rAAV- VEGF-GFP and rAAV-GFP vectors were produced, which were then used to infect human umbilical vein endothelial cells (HUVECs) in order to evaluate in vitro angiogenic activities. Their protein expressions, tagged with green fluorescent protein (GFP), were monitored by confocal microscopy. The functional activities were measured using wound-healing HUVEC migration assays. The number of migrated cells stimulated by both the expressed ANG1 and the VEGF in rAAV-infected HUVECs increased almost twice the number observed in the expressed GFP control. In vivo angiogenic activities of the expressed ANG1 or VEGF were determined using mouse angiogenesis assays. The angiogenic activities of ANG1 or VEGF expressed in the injected mice were increased by 1.36 and 2.16 times, respectively, compared to those of the expressed GFP control. These results demonstrate that the expressed ANG1 derived from rAAV infection has in vitro and in vivo angiogenic activities and suggest that the rAAV-ANG1 vector is a potential strategy for therapeutic angiogenesis.
